Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2007
11/22/2007CA2651354A1 Use of 4,17.beta.-dihydroxyandrost-4-ene-3-one for treating cancers
11/22/2007CA2650232A1 Pharmaceutical combinations
11/22/2007CA2633439A1 Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
11/21/2007EP1857817A1 Screening method
11/21/2007EP1857816A1 Method of screening therapeutic agent for irritable bowel syndrome
11/21/2007EP1857463A1 Peptide having neuroprotective effects
11/21/2007EP1857457A2 Benzimidazole derivative and its use as AII receptor antagonist
11/21/2007EP1857118A1 Medicinal composition for treating diabetes
11/21/2007EP1857115A2 Using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
11/21/2007EP1857113A2 Method and materials for treating asthma
11/21/2007EP1857111A2 Composition comprising a combination of an aromatase inhibitor, a progestin and an estrogen, and its use for the treatment of endometriosis
11/21/2007EP1857108A1 Preventive or therapeutic agent for herpesvirus-related disease
11/21/2007EP1857101A2 Medicaments
11/21/2007EP1855721A1 Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
11/21/2007EP1855718A2 Adhesin as immunogen against escherichia coli
11/21/2007EP1670513A4 Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
11/21/2007EP1490077B1 A photoprotective orally administrable composition for skin
11/21/2007EP1474139B1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
11/21/2007EP1458383B1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
11/21/2007EP1458368B1 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
11/21/2007EP1423102B1 Plaster for the treatment of dysfunctions and disorders of nail growth
11/21/2007EP1405639B1 Use of sodium channel blocking compounds and aspirin in manufacturing drugs for producing synergistic analgesic effect in mammals
11/21/2007EP1385498B1 Fatty acids as neutrophil survival and activation factors.
11/21/2007EP1356071B1 Genetically engineered herpes virus for the treatment of cardiovascular disease
11/21/2007EP1301500B1 Nitrosated and nitrosylated taxanes, compositions and methods of use
11/21/2007EP1269196B1 Method of screening for inhibitors of osteopontin
11/21/2007EP1197226B1 Agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
11/21/2007EP1019087B1 Ganglioside immunostimulating complexes and uses thereof
11/21/2007CN101076585A Bacterial strains, compositions including same and probiotic use thereof
11/21/2007CN101076371A Novel pharmaceutical composition containing at least one dolastatin 10 derivative
11/21/2007CN101076338A Treatment of aml
11/21/2007CN101076331A Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
11/21/2007CN101076328A Preventive or therapeutic agent for sleep disorder
11/21/2007CN101076326A Method of using adapalene in acne maintenance therapy
11/21/2007CN101073668A Antibody compositions for selectively inhibiting vegf
11/21/2007CN101073667A Enhancer for antibody to lymphocytic tumors
11/21/2007CN101073665A Use of lymphotoxin in treatment of medicine for increasing chemoradiotherapeutic sensitivity
11/21/2007CN101073584A Method and compositions for altering cell function
11/21/2007CN101073573A Oral beta-lactam antibiotic slow-release composition
11/21/2007CN101073554A Anti-cancer composition containing tyrosine kinase inhibitor and alkylating agent
11/21/2007CN100349887C Substituted 4-aryl-4H-pyrrolo[2,3-H]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/21/2007CN100349614C Solid mixture containing alpha-amylase and its prepn process and application in pharmaceutical industry
11/20/2007US7297774 Isolated or purified mutated human fibroblast growth factor receptor-4 (FGFR-4) comprising point mutation resulting in replacement of glycine with arginine; tyrosine kinase inhibitors; anticarcinogenic agents
11/20/2007US7297761 Pharmaceutical compositions containing exendins
11/20/2007US7297715 PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
11/20/2007US7297702 Administering during follicular phase in a dosage less than an ovulation-inhibiting or abortion-inductive dose; 11 beta -[(4-N,N-Dimethylamino) -phenyl]-17 beta -hydroxy-17 alpha -propinyl-4,9(10)-estradien-3-one (RU 38486) for example; will not abort previously implanted fetus
11/20/2007US7297696 Antiarthritic agents; antihistamines; atherosclerosis; multiple sclerosis; Crohn's disease; nephritis; pancreastitis; skin disorders; restenosis; prevent leukocyte migration
11/20/2007US7297681 For use in therapy of growth metabolic disorders
11/20/2007US7297526 Human DNase
11/20/2007US7297099 Use of osteopontin for the treatment and/or prevention of neurologic diseases
11/20/2007CA2417843C Administration of an injectable antibiotic in the ear of an animal
11/20/2007CA2328197C Methods for treating neuropsychiatric disorders
11/20/2007CA2262409C Modified tie-2-receptor ligands
11/20/2007CA2211389C Novel pharmaceutical combination
11/15/2007WO2007131154A2 Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
11/15/2007WO2007131005A2 Use of organic compounds
11/15/2007WO2007130842A2 Combination therapy for diseases involving angiogenesis
11/15/2007WO2007130627A2 Il-33 in the treatment and diagnosis of diseases and disorders
11/15/2007WO2007130383A2 Compositions and treatments using pyridazine compounds and secretases
11/15/2007WO2007129745A1 Heteroarylamide lower carboxylic acid derivative
11/15/2007WO2007129522A1 Preparation produced by dry process
11/15/2007WO2007129473A1 Bicyclic aryl derivative
11/15/2007WO2007129290A1 Statins for the treatment of viral influenza infections
11/15/2007WO2007128526A2 Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases
11/15/2007WO2007128493A1 Neuroprotective compounds and uses thereof
11/15/2007WO2007106723A3 Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
11/15/2007WO2007093624A3 Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
11/15/2007WO2007089906A3 Cationic steroid antimicrobial compositions for treating or preventing herpes infections
11/15/2007WO2007087151A3 Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction
11/15/2007WO2007084651A3 Methods and kits to treat chronic inflammatory immune diseases
11/15/2007WO2007079390A3 Medicament for topical use
11/15/2007WO2007076875A3 Compounds acting on the serotonin transporter
11/15/2007WO2007075525A3 Combination of an iap-inhibitor and a taxane7
11/15/2007WO2007048121A3 Methods of preparing targeted immunoliposomes
11/15/2007WO2004103263A3 Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
11/15/2007US20070265285 Quinazolinone derivatives and their use as CB agonists
11/15/2007US20070265280 Methods of using sodium channel blockers
11/15/2007US20070265279 Use of mGluR5 antagonists for the treatment of pruritic conditions
11/15/2007US20070265241 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
11/15/2007US20070265208 Association of calpain inhibitors and reactive oxygen species trapping agents
11/15/2007US20070265194 Agents for the treatment of viral infections
11/15/2007US20070265188 LDL Receptor-Related Proteins 1 and 2 and Treatment of Bone or Cartilage Conditions
11/15/2007US20070264358 Methods and Compositions for Treating Mood Disorder
11/15/2007US20070264348 Nanoparticulate fibrate formulations
11/15/2007US20070264287 Methods for Increasing the Immune Response in an Animal
11/15/2007US20070264267 Nucleotide sequences coding zinc transport protein for use in diagnosis, prevention and treatment of cell proliferative disorders
11/15/2007US20070264257 Immunotherapy of autoimmune disorders
11/15/2007US20070264245 Compositions and minimally invasive methods for treating incomplete tissue repair
11/15/2007US20070264241 Compounds for Enhanced Cancer Therapy
11/15/2007US20070264235 Polypeptide Having an Improved Cytosine Deaminase Activity
11/15/2007US20070264229 Peptides for Treatment of Autoimmune Disease
11/15/2007US20070264228 Methods for treating viral infection using il-28 and il-29
11/15/2007US20070264197 Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection reagents
11/15/2007US20070264194 Peptides That Bind To Atherosclerotic Lesions
11/15/2007DE102007017298A1 New nanoparticles containing nicotine and/or cotinine useful e.g. for cigarette weaning and to treat e.g. attention-deficit hyperactivity disorder, Parkinson's disease, Alzheimer's disease and Binswanger's disease
11/15/2007CA2651194A1 Methods for treating neovascular diseases
11/15/2007CA2650980A1 Statins for the treatment of viral influenza infections
11/15/2007CA2649962A1 Hcv coreceptor and methods of use thereof
11/15/2007CA2649701A1 Use of organic compounds
11/14/2007EP1854880A1 Methods and reagents for modulating cholesterol levels
1 ... 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 ... 1151